Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV

Clinical trial NCT07726433 · RECRUITING

Trial details

NCT number: NCT07726433
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Chemotherapy-Induced Nausea and Vomiting (CINV)

Start date: 2026-06-15
Primary completion: 2028-06-01
Enrollment: 56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.